Optimal Control of Liver Metastases From Colorectal Cancer With Cetuximab and Hepatic Artery Infusion of Chemotherapy
Optimal Control of Liver Metastases With Intravenous Cetuximab and Hepatic Artery Infusion of Three-drug Chemotherapy in Patients With Liver-only Metastases From Colorectal Cancer. A European Multicenter Phase II Trial
Sponsor: Association pour la Recherche sur le Temps Biologique et la Chronothérapie
This PHASE2 trial investigates Hepatic Lesions and Liver Metastases and is currently ongoing. Association pour la Recherche sur le Temps Biologique et la Chronothérapie leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Jul 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Association pour la Recherche sur le Temps Biologique et la Chronothérapie
- CRESGE
- Gustave Roussy, Cancer Campus, Grand Paris
- Merck Serono International SA
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amadora, Portugal , Bordeaux, France , Boulogne-Billancourt, France , Chieti, Italy , Clermont-Ferrand, France , Lille, France , Liège, Belgium , Paris, France , Pordenone, Italy , Roma, Italy and 2 more locations